Solid Biosciences (SLDB) — Next-generation gene therapy for Duchenne, Friedreich’s ataxia and rare cardiac disease

Solid Biosciences Inc. (NASDAQ: SLDB) is a precision genetic medicines company headquartered in the United States, focused on developing transformative AAV-based gene therapies for rare neuromuscular and cardiac diseases. The company occupies a distinctive position in the gene therapy landscape: rather than concentrating on a single indication or a single vector platform, Solid has built a multi-program, multi-indication pipeline underpinned by a proprietary next-generation capsid — AAV-SLB101 — which it both uses internally and licenses externally.

The company’s lead clinical program, SGT-003, targets Duchenne muscular dystrophy, a fatal X-linked disease affecting approximately 1 in 3,500 male births worldwide. The program is evaluated in two active clinical studies: the Phase 1/2 INSPIRE DUCHENNE (first-in-human, multi-center, United States and international sites) and the Phase 3 IMPACT DUCHENNE (ex-U.S., randomized, double-blind, placebo-controlled). Beyond Duchenne, Solid is pursuing SGT-212 for Friedreich’s ataxia (FALCON Phase 1b) and SGT-501 for catecholaminergic polymorphic ventricular tachycardia — CPVT (ARTEMIS Phase 1b), two additional rare diseases with critical unmet therapeutic needs.

A further dimension of Solid’s strategy is the commercialization of its AAV-SLB101 capsid technology via access and licensing agreements with more than 50 corporate, institutional and academic partners as of early 2026. This platform approach serves multiple purposes: it generates independent scientific validation of the capsid, creates potential future revenue streams from milestones and royalties, and provides a degree of financial resilience that is uncommon among early-stage biotech companies of comparable size.

Origins: a patient-centric DMD mission

Solid Biosciences was founded with a clear and urgent focus: to develop a gene therapy for Duchenne muscular dystrophy at a time when the disease had no approved treatment capable of addressing its root genetic cause. Dystrophin — the protein encoded by the largest gene in the human genome — is absent or severely deficient in Duchenne patients due to mutations in the DMD gene, resulting in progressive loss of skeletal and cardiac muscle function, loss of ambulation in early adolescence, and eventual cardiorespiratory failure. The founders believed that AAV-mediated microdystrophin gene therapy offered the most direct path toward a transformative, potentially single-treatment solution.

SGT-001 and the IGNITE DMD experience

Solid’s first clinical candidate was SGT-001, an AAV9-based gene therapy delivering a microdystrophin transgene, evaluated in the IGNITE DMD Phase 1/2 trial. IGNITE DMD generated important proof of concept, demonstrating that intravenous delivery of a microdystrophin gene therapy could produce durable protein expression in the skeletal muscle of Duchenne patients across multiple biopsies and follow-up time points. This was a landmark scientific result, establishing the feasibility of the approach.

However, the program also encountered the safety challenges that characterized first-generation systemic AAV therapies across the industry. Serious immune-mediated adverse events — including reactions consistent with complement activation and hepatic stress responses — led to multiple FDA-imposed clinical holds and required significant revisions to the dosing protocol, immunosuppression regimen and eligibility criteria. These events, while resolved without catastrophic outcomes, underscored the importance of capsid engineering and immunology management in high-dose systemic gene therapy, and informed Solid’s decision to redesign its approach at the foundational level.

The AavantiBio acquisition and strategic pivot

A defining moment in Solid’s evolution came in late 2022 with the completion of the acquisition of AavantiBio, a biotechnology company specializing in cardiac gene therapy. This deal brought three critical assets to Solid: (1) a gene therapy program for Friedreich’s ataxia that would eventually become SGT-212; (2) an early cardiac program targeting CPVT, later developed into SGT-501; and (3) most importantly, the intellectual property and scientific expertise underlying the proprietary next-generation capsid that became AAV-SLB101.

The acquisition fundamentally repositioned Solid. Rather than continuing to iterate on AAV9-based constructs within the constraints of a first-generation capsid, the company now had the building blocks for a more differentiated approach: a proprietary capsid engineered specifically for muscle and cardiac tropism, combined with an optimized transgene architecture. The strategic logic was compelling — if AAV-SLB101 could deliver equivalent or better gene expression in skeletal and cardiac muscle at doses associated with a more manageable safety profile, Solid could potentially develop the best-in-class Duchenne gene therapy while simultaneously applying the same platform to Friedreich’s ataxia and CPVT.

From SGT-001 to SGT-003: the next-generation redesign

Based on the learnings from IGNITE DMD and the new capabilities from AavantiBio, Solid formally deprioritized SGT-001 and committed resources to SGT-003, a redesigned Duchenne gene therapy that differs from its predecessor in two key respects. First, the transgene includes nNOS-binding spectrin-like repeat domains R16 and R17, which are absent in most other microdystrophin constructs. Neuronal nitric oxide synthase anchoring at the sarcolemma is functionally important: its loss in DMD contributes to impaired blood flow regulation during exercise (functional ischemia), fatigue and additional muscle damage pathways. By including the R16/R17 domains, Solid’s microdystrophin aims to restore not only structural integrity but also this metabolic/vascular regulatory function in muscle.

Second, SGT-003 uses the AAV-SLB101 capsid, which is engineered to enhance transduction efficiency in skeletal and cardiac muscle while reducing liver biodistribution relative to AAV9. This combination — optimized transgene plus next-generation capsid — is the scientific foundation for Solid’s claim that SGT-003 could offer an improved benefit/risk profile compared to both the company’s own first-generation program and other capsid/transgene combinations being developed by competitors.

By early 2026, that hypothesis is being tested in clinical practice. INSPIRE DUCHENNE has dosed 33 participants aged 1–10, and the emerging data are being closely watched by the Duchenne community, investors and competitors alike. Meanwhile, the broader platform strategy — FALCON for Friedreich’s ataxia, ARTEMIS for CPVT and the growing network of capsid licensing agreements — reflects the maturation of Solid from a single-indication startup into a platform- driven company with diversified value creation potential.

Duchenne muscular dystrophy

Duchenne muscular dystrophy is the most common and severe form of muscular dystrophy in children. Caused by out-of-frame mutations or large deletions in the X-linked DMD gene, it results in a near-total absence of functional dystrophin protein in all muscle types. In boys — who bear the full impact of the hemizygous mutation — the disease manifests as early childhood proximal muscle weakness, progressive loss of walking ability typically by ages 10–12, followed by respiratory insufficiency requiring ventilatory support and cardiomyopathy that becomes the dominant cause of death in the second and third decades of life.

Current standard of care rests on corticosteroids (deflazacort, prednisone/prednisolone), which slow disease progression but carry significant side effects and do not correct the genetic defect. Several exon-skipping agents targeting specific deletion subgroups (eteplirsen for exon 51 skip, golodirsen, viltolarsen, casimersen) are approved for subpopulations of patients, but their efficacy evidence remains debated and they are applicable only to patients with mutations amenable to skipping of specific exons. One mini-dystrophin gene therapy, delandistrogene moxeparvovec (Elevidys, from Sarepta Therapeutics), received accelerated FDA approval in 2023, becoming the first approved gene therapy for DMD. However, its label has evolved, and the competitive and regulatory context continues to develop rapidly, making this one of the most watched indications in gene therapy.

Against this backdrop, next-generation programs like SGT-003 aim to differentiate on: (1) expression levels and durability of microdystrophin in both skeletal and cardiac muscle; (2) the functional impact of including nNOS-binding domains; and (3) the safety/tolerability profile enabled by novel capsids such as AAV-SLB101. The cardiac dimension is particularly important: cardiomyopathy is now the leading cause of death in Duchenne, and existing therapies address it inadequately.

Friedreich’s ataxia

Friedreich’s ataxia is the most common inherited ataxia in the Western world, affecting approximately 1 in 50,000 people. It is caused predominantly by a biallelic intronic GAA trinucleotide repeat expansion in the FXN gene, which silences frataxin expression through epigenetic mechanisms. Frataxin is a mitochondrial protein essential for iron-sulfur cluster assembly and protection against oxidative damage; its deficiency leads to mitochondrial dysfunction, progressive neurodegeneration (particularly of the dorsal root ganglia, spinocerebellar tracts and cerebellar dentate nucleus), hypertrophic cardiomyopathy and diabetes mellitus in a significant proportion of patients.

The median age at death is in the late 30s to early 40s, with cardiomyopathy accounting for most fatalities. In 2023, omaveloxolone (Skyclarys, Biogen/Reata) became the first FDA-approved treatment for Friedreich’s ataxia in patients aged 16 and older, offering a modest but statistically significant improvement in neurological function. However, it does not restore frataxin expression, is not universally applicable, and leaves the cardiac manifestations largely unaddressed. Gene therapy approaches that restore frataxin — such as SGT-212 — therefore address a fundamentally different mechanism and have the potential for disease modification at the source, though clinical validation remains ongoing.

Catecholaminergic polymorphic ventricular tachycardia

CPVT is a rare inherited arrhythmia syndrome characterized by the occurrence of bidirectional or polymorphic ventricular tachycardia in response to physical or emotional stress, in the absence of structural heart disease or QTc prolongation. The most common genetic subtype (CPVT1) is caused by autosomal dominant mutations in RYR2, encoding ryanodine receptor 2 in cardiac myocytes; a less frequent form (CPVT2) involves recessive mutations in CASQ2, encoding calsequestrin. Both defects lead to pathological calcium leak from the sarcoplasmic reticulum during adrenergic stimulation, triggering fatal ventricular arrhythmias.

The estimated prevalence is 1 in 10,000 and the condition is frequently underdiagnosed, with sudden cardiac death sometimes being the first presentation. Current management includes high-dose beta-blockade, flecainide, and in refractory cases, left cardiac sympathetic denervation (LCSD) or implantable cardioverter-defibrillators (ICDs). None of these modalities correct the underlying ion channel dysfunction. A gene therapy approach like SGT-501 that delivers a functional copy of the relevant gene to cardiac myocytes represents a potential curative strategy in a disease where pharmacologic control is often inadequate and ICDs do not prevent all arrhythmic events.

Engineering rationale for AAV-SLB101

The development of next-generation AAV capsids for systemic gene therapy is driven by the need to overcome three limitations of first-generation vectors: (1) off-target liver transduction leading to hepatotoxicity at therapeutically relevant doses; (2) suboptimal muscle/cardiac tropism requiring higher doses to achieve efficacy, which in turn increases immune activation risk; and (3) pre-existing neutralizing antibodies in a substantial fraction of patients, which can exclude them from treatment.

AAV-SLB101 was engineered with these challenges in mind. It is described as demonstrating enhanced transduction of skeletal and cardiac muscle relative to AAV9-based vectors, with a simultaneously reduced biodistribution to the liver. The practical consequence, if the preclinical and early clinical data hold, is a wider therapeutic window: equivalent or greater muscle expression at doses low enough to maintain a manageable hepatic safety profile. This is particularly valuable in Duchenne, where patients are young children with developing immune systems and where even moderate hepatic stress can complicate clinical management.

Clinical data from INSPIRE DUCHENNE, while still maturing, are consistent with this hypothesis. Up to the January 2026 data cutoff, the 33 participants dosed with SGT-003 — which uses AAV-SLB101 as its delivery vehicle — have shown no cases of drug-induced liver injury (DILI), thrombotic microangiopathy (TMA), atypical hemolytic uremic syndrome (aHUS) or myocarditis. The prophylactic immunosuppression regimen has relied on corticosteroids alone, without the more intensive immunomodulation that has been required in some competitive programs. While this is promising, longer follow-up across a larger cohort will be essential to confirm that this favorable profile is maintained over time.

Manufacturing and process development

The ability to manufacture high-quality AAV at scale is a strategic constraint in gene therapy, and Solid has made significant investments in developing scalable, GMP-compatible production processes for SGT-003 and its broader pipeline. The company employs a transient plasmid transfection-based production system using suspension cell cultures, which offers greater scalability than adherent cell formats and is well-suited to the large vector quantities required for systemic DMD gene therapy.

As programs advance into later-stage trials and potentially toward commercialization, demonstrating comparability between clinical-scale and commercial-scale manufacturing batches — including consistent vector genome per dose, full/empty capsid ratio, transduction efficiency and potency — will be a regulatory priority. The development of robust, validated analytical assays for AAV-SLB101-based products will be a critical enabler of this process.

External platform: the AAV-SLB101 licensing ecosystem

Beyond its internal programs, Solid has executed more than 50 access and licensing agreements granting external partners the right to use AAV-SLB101 in their own research and development programs. These partners include pharmaceutical companies, biotech start-ups, research institutions and academic laboratories. The strategic rationale for this is multifold. Each external program that uses AAV-SLB101 generates independent scientific data on the capsid’s performance across different payloads, cell types and indications, effectively broadening the evidence base without direct investment by Solid. Successful partner programs could generate milestone payments and royalties in the medium term, providing a non-dilutive revenue stream. And the growing network of AAV-SLB101 users enhances Solid’s profile as a credible platform company rather than a single-product developer.

SGT-003 and INSPIRE DUCHENNE — detailed analysis

SGT-003 is Solid’s most advanced and most closely watched asset. As of January 9, 2026, thirty-three boys aged one to ten years have been dosed in INSPIRE DUCHENNE, the Phase 1/2 open-label trial designed to evaluate safety, tolerability and early efficacy signals of a single intravenous infusion of SGT-003 at the target dose of 1×10¹⁴ vg/kg. The trial enrolls participants across two age cohorts — under 7 years and 7 to 10 years — with the younger cohort of particular scientific interest because early intervention may preserve more muscle tissue before disease-related degeneration becomes established.

The most important near-term question for INSPIRE DUCHENNE is whether the robust preclinical transduction profile of AAV-SLB101 translates into high, uniform and durable microdystrophin expression in human muscle biopsies. Early data presented in 2025, covering 90-day post-dosing biopsies in the initial cohort participants, showed compelling microdystrophin expression levels in skeletal muscle, accompanied by significant reductions in serum biomarkers of muscle damage — creatine kinase, aspartate aminotransferase, alanine aminotransferase and lactate dehydrogenase — consistent with a biological effect on muscle integrity. Cardiac function assessments showed early signals of improvement in left ventricular ejection fraction in a subset of participants, though the cardiac dataset is preliminary and requires larger numbers and longer follow-up.

From a safety standpoint, the profile observed through the January 2026 cutoff is notably clean relative to some competitive programs. Prophylaxis with oral corticosteroids alone has been sufficient to manage immune responses without escalation to more aggressive immunomodulatory agents such as complement inhibitors, intravenous immunoglobulin or plasmapheresis. No participant has been discontinued due to a serious drug-related adverse event, and the trial remains on track with ongoing enrollment.

The Phase 3 program, IMPACT DUCHENNE, operates under a different design paradigm. It is randomized, double-blind and placebo-controlled — the regulatory gold standard — and is being conducted outside the United States at sites in Canada, Australia and multiple European countries. IMPACT is designed to provide the confirmatory efficacy evidence that would support full approval or accelerated approval conversion in major regulatory jurisdictions. The ex-U.S. nature of the trial reflects a deliberate strategy to advance the program in parallel in markets where the regulatory and reimbursement environment for gene therapies is evolving, including the United Kingdom’s Innovative Licensing and Access Pathway (ILAP) designation that Solid has obtained for SGT-003. First dosing in IMPACT was anticipated for the first quarter of 2026, with enrollment expected to build through the year.

SGT-212 and FALCON — Friedreich’s ataxia first-in-human

SGT-212 represents one of the most scientifically ambitious programs in Solid’s portfolio. It is the only gene therapy in clinical development for Friedreich’s ataxia that employs a dual-route delivery strategy, combining direct administration to the intradentate nuclei of the cerebellum — using MRI-guided stereotactic injection — with a systemic intravenous infusion. The rationale for this approach is grounded in the pathophysiology of Friedreich’s ataxia: the disease simultaneously affects the central nervous system (particularly the cerebellar dentate nucleus and dorsal root ganglia) and peripheral tissues including the heart. Single-route delivery — either intrathecal or systemic alone — has limitations in achieving adequate frataxin restoration in both compartments simultaneously.

The dual-route approach is more operationally complex and carries higher procedural risk per dose than a purely systemic infusion, but Solid believes the potential for more comprehensive frataxin restoration justifies this complexity. The FALCON Phase 1b trial has dosed its first participant, and initial safety and biomarker data — including frataxin protein levels in CSF and blood, cardiac imaging endpoints and neurological assessments — are anticipated in the second half of 2026, subject to enrollment pace.

The regulatory package supporting SGT-212 is notably strong. The program has received FDA Orphan Drug Designation, Fast Track Designation and Rare Pediatric Disease Designation, the latter being particularly valuable because it creates eligibility for a Priority Review Voucher upon approval — an instrument that has historically been sold for values ranging from approximately $100 million to more than $150 million in the secondary market, providing a significant non-dilutive financial benefit if the program reaches the finish line. The competitive landscape in FA gene therapy remains sparse, positioning SGT-212 as a potential first-in-class agent if its clinical profile is validated.

SGT-501 and ARTEMIS — first-in-human CPVT gene therapy

In CPVT, Solid occupies what is effectively a competitive white space. There is no gene therapy currently in clinical development for this indication by any competitor, making SGT-501 a genuine first-mover in an ultra-rare but medically serious condition. The ARTEMIS Phase 1b trial has activated clinical sites and is screening eligible patients; given the small patient population and the need to identify individuals with confirmed genetic diagnoses and adequate disease burden, enrollment will take time, but the first safety data are planned for the second half of 2026.

For CPVT, the key early endpoints are cardiac safety (with particular attention to pro-arrhythmic risk of the gene therapy itself and the procedural intervention) and pharmacodynamic signals such as changes in resting and stress-induced arrhythmia frequency, measured by Holter monitoring and exercise stress testing. If SGT-501 demonstrates an acceptable safety profile with even preliminary evidence of arrhythmia reduction, it will establish a foundation for a potentially transformative treatment in a population that currently lives under the constant risk of sudden cardiac death despite maximal pharmacologic management.

DMD gene therapy: an evolving, crowded field

The Duchenne gene therapy space has become one of the most competitive in all of rare disease medicine. Delandistrogene moxeparvovec (Elevidys, Sarepta Therapeutics) was granted accelerated FDA approval in June 2023 for ambulatory patients aged 4 to 5 years, making it the first approved Duchenne gene therapy. The approval was subsequently expanded to ambulatory patients aged 4 and older, though it was not extended to non-ambulatory patients following a confirmatory trial read-out that did not show statistical significance on the primary functional endpoint in the broader ambulatory population. This regulatory evolution underscores both the commercial opportunity (first-mover advantage for Sarepta) and the evidentiary challenges (functional endpoints in DMD are difficult to power and interpret) that all programs in this space must navigate.

Other programs in the competitive landscape include earlier-stage assets from multiple companies, some using AAV capsids other than AAV-SLB101 and some employing transgene designs without nNOS-binding domains. Solid’s differentiation thesis centers on three claims: (1) AAV-SLB101 delivers better muscle/cardiac tropism with lower hepatic exposure than standard AAV9; (2) the R16/R17 nNOS-binding domains in the SGT-003 microdystrophin provide a superior functional benefit, particularly for cardiac and vascular regulation; and (3) the resulting safety/tolerability profile supports single-dose treatment with steroid-only prophylaxis in young children. Whether these claims ultimately translate into a clinically and commercially differentiated product will be determined by the outcomes of INSPIRE and IMPACT DUCHENNE over the next two to three years.

Friedreich’s ataxia: limited but growing competition

While omaveloxolone (Skyclarys) has established a commercial precedent in FA, the gene therapy space for this indication remains sparse. The complexity of frataxin biology, the dual-tissue nature of the disease (CNS and cardiac) and the challenge of GAA repeat silencing have made it technically difficult to develop a single-route gene therapy with compelling efficacy across all target tissues. Solid’s dual-route approach with SGT-212 is unique in the clinical landscape and is positioned as the most scientifically comprehensive attempt at frataxin restoration currently in clinical trials. Early readouts from FALCON will be closely watched by the broader rare disease investment community.

CPVT: a virtually uncontested space

In CPVT, Solid has no direct gene therapy competitor in the clinic as of February 2026. The rarity of the disease, the complexity of cardiac gene therapy development and the limited commercial potential of ultra-rare cardiac indications have historically deterred large companies. For a platform company like Solid, however, the opportunity to establish a first-in-class cardiac gene therapy in CPVT is attractive both scientifically and strategically, as it validates the cardiac capabilities of AAV-SLB101 and creates an independent value-creation pathway beyond Duchenne.

Solid Biosciences is a pre-revenue company at this stage of its development. All revenues in recent periods have been nominal, and the company’s financial results are dominated by research and development expenditures associated with the advancement of its clinical programs and platform activities. Understanding its financial profile requires focusing on three dimensions: cash runway, burn rate trajectory and capital structure.

Path to potential revenue

Solid’s roadmap to revenue has three potential vectors: (1) regulatory approval and commercial sales of SGT-003 (earliest realistic scenario: 2027–2028, depending on the outcome of INSPIRE and IMPACT DUCHENNE and the regulatory strategy chosen); (2) milestone and royalty income from AAV-SLB101 licensing agreements as partner programs advance; and (3) potential partnership or out-licensing deals for one or more pipeline programs that could generate upfront payments and development cost-sharing. None of these revenue streams is guaranteed, and investors should treat Solid as a binary-event-driven story for the foreseeable future.

• INSPIRE DUCHENNE — additional data updates (mid-2026 and beyond): additional data presentations covering larger cohorts, longer follow-up and functional assessments (e.g., North Star Ambulatory Assessment, pulmonary function, cardiac MRI) are the single most important catalyst for SLDB’s near-term valuation. Positive, durable data would materially de-risk the program and provide the foundation for a regulatory dialogue on accelerated approval or a rolling NDA submission.
• IMPACT DUCHENNE — first dosing and enrollment ramp (Q1 2026 onward): initiation of the randomized Phase 3 trial signals execution capability and regulatory confidence. Enrollment velocity will be closely monitored as an indicator of site activation quality and patient community engagement in Canada, Australia, the UK (ILAP) and European sites.
• FDA regulatory interactions for SGT-003: meetings with the FDA to define the path to accelerated or full approval — including acceptable endpoints, time points and statistical thresholds — are a critical catalyst that can substantially reduce development risk if the outcome is constructive.
• FALCON (SGT-212, FA) — first safety and biomarker readout (H2 2026): the first human data from a dual-route frataxin gene therapy will be a landmark event in the FA field regardless of outcome, with potential for substantial positive re-rating if safety is acceptable and frataxin levels in relevant compartments show meaningful increases.
• ARTEMIS (SGT-501, CPVT) — initial safety data (H2 2026): first-in-human cardiac gene therapy data for CPVT will demonstrate whether the AAV-SLB101 platform can be safely deployed in a cardiac setting, opening a new dimension of value for the capsid independently of DMD outcomes.
• AAV-SLB101 platform — additional licensing and partnership deals: continued expansion of the external licensing ecosystem toward and beyond 50 agreements, including any material corporate partnership that generates upfront cash or validates the platform’s commercial attractiveness.

Retail investor perspective

Retail interest in SLDB is characteristic of the Duchenne and gene therapy investment community: a combination of long-term patient advocates and family members who invest with conviction in the mission, science-driven retail investors following the AAV gene therapy space, and event-driven traders who position around clinical data presentations and regulatory announcements. The stock’s volatility pattern reflects this mix — relatively calm periods punctuated by sharp moves around data readouts, conference presentations and press releases.

Social media and advocacy community sentiment around SLDB has been cautiously optimistic since the positive 90-day INSPIRE DUCHENNE data presentations in 2025, particularly within the Duchenne parent and patient community where SGT-003’s safety profile (steroid-only prophylaxis, no DILI/TMA/aHUS) has been favorably noted relative to the broader history of the field. However, retail traders are also aware that the Duchenne gene therapy space has a history of disappointments and regulatory setbacks, and many are waiting for longer-term functional data before increasing exposure.

Key retail sentiment drivers going forward will be: (1) the quality and completeness of the next INSPIRE data cut and whether functional endpoints begin to show a meaningful signal; (2) the pace of IMPACT DUCHENNE enrollment, which is seen as a proxy for clinical confidence; and (3) whether SGT-212 and SGT-501 data confirm the breadth of the AAV-SLB101 platform story or introduce unexpected complications. Short interest in SLDB, as with most small-cap gene therapy names, should be monitored, as it can amplify both upside (short squeezes on positive data) and downside (add-on short pressure on negative events).

Insider posture and management signals

Management communications consistently emphasize a long-term platform-building narrative rather than a near-term event-driven story. The decision to pursue the ex-U.S. Phase 3 IMPACT DUCHENNE trial — a significant operational and financial commitment — signals that management has confidence in the SGT-003 data and is preparing for a full regulatory submission rather than relying solely on accelerated approval based on surrogate endpoints. The acquisition of AavantiBio and the deliberate diversification into Friedreich’s ataxia and CPVT reinforce the message that this leadership team views Solid as a multi-product, multi-indication company with a durable technology moat.

For granular insider trading data (Form 4 filings showing individual executive and director purchases and sales), investors should consult SEC EDGAR directly at Solid Biosciences Form 4 filings on EDGAR. Patterns of insider buying on the open market — particularly at current price levels — would be a constructive signal, while concentrated selling by multiple insiders would warrant closer scrutiny. In general, for clinical-stage biotech companies, insider purchases made outside of planned trading windows carry the most informational weight.

This document is provided for educational and informational purposes only. It does not constitute investment advice, a solicitation, an offer or a recommendation to buy or sell any security. The information contained herein is derived from publicly available sources believed to be reliable as of the date of publication, but no representation or warranty, express or implied, is made as to its accuracy, completeness or timeliness. Clinical data, regulatory decisions and financial information for biotechnology companies can change rapidly and materially. Investing in early-stage biotechnology companies such as Solid Biosciences involves substantial risk, including the possible loss of all invested capital. Past stock performance is not indicative of future results. Readers should conduct their own due diligence and consult a licensed financial adviser before making any investment decision related to SLDB or any other security referenced herein.